NDA 220748 · Avyxa Holdings
Axycis
Cisplatin · Intravenous · Platinum-based Drug
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Oct 29, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
4,792
1,209 Phase 3, 731 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: NEPHROTOXICITY, PERIPHERAL NEUROPATHY, NAUSEA AND VOMITING, AND MYELOSUPPRESSION Nephrotoxicity: AXYCIS can cause severe renal toxicity, including acute renal failure. Severe renal toxicities are dose-related and cumulative. Ensure adequate hydration and monitor renal function and electrolytes. Consider dose reductions or alternative treatments in patients with renal impairment [see Dosage and Administration (2.1) and Warnings and Precautions (5.1) ]. Peripheral Neuropathy: AXYCIS can cause dose-related peripheral neuropathy that becomes more severe with repeated courses of the drug [see Warnings and Precautions (5.2) ]. Nausea and Vomiting: AXYCIS can cause severe nausea and vomiting. Administer pre-treatment and post-treatment antiemetics as clinically indicated [see Dosage and Administration (2.1) and Warnings and Precautions (5.3) ]. Myelosuppression: AXYCIS can cause...
What it is approved for
From the label in effect Nov 12, 2026.
AXYCIS is a platinum-based drug indicated for the treatment of: Advanced testicular cancer ( 1.1 ) Advanced ovarian cancer ( 1.2 ) Advanced bladder cancer ( 1.3 ) 1.1 Advanced Testicular Cancer AXYCIS is indicated for the treatment of advanced testicular cancer. 1.2 Advanced Ovarian Cancer AXYCIS is indicated for the treatment of advanced ovarian cancer. 1.3 Advanced Bladder Cancer AXYCIS is indicated for the treatment of advanced bladder cancer.
Mechanism: Cisplatin is a platinum-based drug that binds to DNA and forms DNA cross-links. These crosslinks inhibit DNA replication and transcription and trigger cytotoxic processes that lead to cell death.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- AXYCIS · CISPLATIN 50MG/50ML (1MG/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Cisplatin" as an intervention, any sponsor and status, largest first.
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02194738 · 7,458 participants · Start Sep 26, 2014 · Primary completion Dec 3, 2025
Drug: Carboplatin; Cisplatin and 8 more · For: Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Cancer AJCC v8 and 4 more
Sites: Birmingham, Alabama; Daphne, Alabama; Mobile, Alabama · 1,660 sites in all
- Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationRecruiting
Hunan Province Tumor HospitalAcademic, hospital or other
NCT04322890 · 6,000 participants (planned) · Start Apr 16, 2020 · Primary completion Dec 24, 2026
Drug: Osimertinib; Alectinib 150 MG and 3 more · For: Non Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation and 2 more
Sites: Changsha, China
- High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)Pivotal-lookingCompleted
St. Anna KinderkrebsforschungAcademic, hospital or other
NCT01704716 · 3,569 participants · Start Feb 1, 2002 · Primary completion Jan 30, 2025
Drug: Vincristine; Aldesleukin and 9 more · For: Neuroblastoma
Sites: Newcastle, Australia; Sydney, Australia; Vienna, Austria · 122 sites in all
- Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung CancerPivotal-lookingCompleted
Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
NCT00002823 · 3,300 participants (planned) · Start Feb 1995 · Primary completion Jan 2001
Drug: cisplatin; etoposide and 3 more · For: Lung Cancer
Sites: Atlantis, Florida; Boston, Massachusetts; Buenos Aires, Argentina · 123 sites in all
- Master Protocol for Basket Clinical Trials of Targeted Therapies Based on Proteome and Whole Exome Sequencing Screening in Patients With Advanced Solid TumorsActive, not recruiting
National Cancer Center, KoreaGovernment (non-federal)
NCT07891169 · 2,800 participants (planned) · Start Nov 18, 2024 · Primary completion Dec 31, 2028
Drug: Homologous Recombination Deficiency (HRD); ALK/ROS1/MET and 1 more · For: Advanced Solid Tumors; Metastatic Solid Tumors; Locally Advanced Solid Tumors and 4 more
Sites: Goyang, South Korea; Goyang-si, South Korea
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT02477826 · 2,747 participants · Start Aug 5, 2015 · Primary completion Oct 25, 2024
Drug: Nivolumab; Ipilimumab and 5 more · For: Non-Small Cell Lung Cancer
Sites: Mobile, Alabama; San Francisco, California; New Haven, Connecticut · 290 sites in all
- Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00619359 · 2,322 participants · Start Feb 2008 · Primary completion Jun 2009
Drug: Comparator: fosaprepitant dimeglumine; Comparator: Aprepitant and 3 more · For: Chemotherapy-Induced Nausea and Vomiting (CINV)
University of ZurichAcademic, hospital or other
NCT00490360 · 2,007 participants · Start Oct 2001
Drug: Gemcitabine / Cisplatin · For: Cancer of the Pancreatic Head
Sites: Zurich, Switzerland
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.
Oh DY, He AR, Bouattour M, et al. · Lancet Gastroenterol Hepatol 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial.
Bourhis J, Aupérin A, Borel C, et al. · Lancet 2026 · Clinical Trial, Phase III, Comparative Study
- Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
Valle J, Wasan H, Palmer DH, et al. · N Engl J Med 2010 · Clinical Trial, Phase III, Comparative Study
- Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.
van der Heijden MS, Sonpavde G, Powles T, et al. · N Engl J Med 2023 · Comparative Study, Randomized Controlled Trial
- Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer.
Galsky MD, Valderrama BP, Maruzzo M, et al. · N Engl J Med 2026 · Clinical Trial, Phase III, Comparative Study
- Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials.
· Eur Urol 2022 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Avyxa Holdings
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.